Afficher la notice abrégée

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

dc.rights.licenseopenen_US
dc.contributor.authorBERNARDINO, J. I.
dc.contributor.authorMOCROFT, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWALLET, Cedrick
dc.contributor.authorDE WIT, S.
dc.contributor.authorKATLAMA, C.
dc.contributor.authorREISS, P.
dc.contributor.authorMALLON, P. W.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
dc.contributor.authorMOLINA, J. M.
dc.contributor.authorKNOBEL, H.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORLAT, Philippe
dc.contributor.authorBABIKER, A.
dc.contributor.authorPOZNIAC, A.
dc.contributor.authorRAFFI, F.
dc.contributor.authorARRIBAS, J. R.
dc.date.accessioned2020-05-15T09:03:42Z
dc.date.available2020-05-15T09:03:42Z
dc.date.issued2019
dc.identifier.issn1932-6203 (Electronic) 1932-6203 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7583
dc.description.abstractEnBACKGROUND: Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. DESIGN: Randomised Clinical Trial. METHODS: This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 805 ART naive HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). RESULTS: 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per 48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026). CONCLUSIONS: After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/us/
dc.subject.enSISTM
dc.subject.enMORPH3Eus
dc.subject.enFR
dc.title.enBody composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
dc.title.alternativePLoS Oneen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pone.0209911en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30689664en_US
dc.description.sponsorshipEuropeEuropean AIDS Treatment Networken_US
bordeaux.journalPLoS ONEen_US
bordeaux.pagee0209911en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSISTM_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=PLoS%20ONE&amp;rft.date=2019&amp;rft.volume=14&amp;rft.issue=1&amp;rft.spage=e0209911&amp;rft.epage=e0209911&amp;rft.eissn=1932-6203%20(Electronic)%201932-6203%20(Linking)&amp;rft.issn=1932-6203%20(Electronic)%201932-6203%20(Linking)&amp;rft.au=BERNARDINO,%20J.%20I.&amp;MOCROFT,%20A.&amp;WALLET,%20Cedrick&amp;DE%20WIT,%20S.&amp;KATLAMA,%20C.&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_PO_2019_Bernardino.pdf
Taille:
1.140Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée